常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.06/-0.66
|
|
企業價值
44.80M
|
| 資產負債 |
|
每股賬面淨值
0.48
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
11.98M
|
|
每股收益
0.92
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2025/11/16 15:49 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| LAVA Therapeutics NV isa clinical stage immuno-oncology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer. Company's pipeline include's products such as LAVA-1266, LAVA-1427, LAVA-1433, LAVA-1207, PF08046052, JNJ89853413. |

1.65 
